New Issue | CNS & Neurological Disorders – Drug Targets; Volume 18 Issue 10

 

cnsnddt

 

CNS & Neurological Disorders – Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders – Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

 

Articles from the journal: CNS & Neurological Disorders – Drug Targets; Volume 18 Issue 10

 

 

 

For details on the articles, please visit this link: http://www.eurekaselect.com/node/646/cns-neurological-disorders-drug-targets-/issue/18/2538/10/9564

MOST ACCESSED ARTICLE – Targeted Nanoparticles for the Treatment of Alzheimer’s Disease – Current Pharmaceutical Design

Journal: Current Pharmaceutical Design

Author(s): Rafael Martín-Rapun, Laura De Matteis, Alfredo Ambrosone, Sonia Garcia-Embid, Lucia Gutierrez, Jesus M. de la Fuente

Abstract:

Background: Alzheimer’s disease (AD) has a dramatic impact on society. The therapeutic targets are located in the central nervous system (CNS), which limits the efficacy of drugs systemically administered: the blood-brain barrier (BBB) selectively allows the permeation of just a few kinds of molecules from the systemic circulation to the CNS. On the other hand, local administration routes to CNS are highly invasive.

Methods: In this article, we have reviewed therapeutic approaches against AD, which are based on nanoparticles targeted to the brain and to the pathological hallmarks of the disease. The existing literature has been classified according to the AD feature that is addressed.

Results: Nanoparticles have been used for the targeted delivery of drugs aiming to reduce the AD symptoms or to reverse the course of the disease. For this task the multivalency of nanoparticles has allowed their functionalization with several kinds of targeting groups, to cross the BBB and to target the place of treatment. With this approach an increased drug bioavailability has been achieved in the CNS using intravenous administration in place of more invasive administration routes. Additionally, nanoparticles have also been used in the development of vaccines and therapeutic formulations for intranasal administration.
Conclusion: Targeted nanoparticles have been proved useful to enhance the performance of therapies against AD in animal models. A better understanding of AD mechanisms will help the successful application of targeted nanoparticles for combined therapies.

To access the article, please visit: http://www.eurekaselect.com/148709

%d bloggers like this: